Xspray Pharma AB (publ) (0GHZ.L)

44,00 +0,10 (+0,23%) In data: 04:39PM BST. Mercato aperto.

Xspray Pharma AB (publ)

Scheeles väg 2
Solna 171 65
Sweden
46 87 30 37 00
https://www.xspraypharma.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 26

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Per Andersson Ph.D.	Chief Executive Officer	3,74M	N/D	1967
Dr. Mustafa Demirbüker Ph.D.	Co-Founder and Science Director	N/D	N/D	N/D
Mr. Michael af Winklerfelt	Acting Chief Financial Officer	N/D	N/D	1972
Mr. Gérald Jesson	Vice President of Operations	N/D	N/D	N/D
Ms. Kerstin Hasselgren	Senior Advisor & Head of IR	N/D	N/D	1961
Ms. Linda Glimberg	Senior Vice President of Legal	N/D	N/D	1974
Ms. Charlotta Liljebris	Senior Vice President of Research & Development	N/D	N/D	1964
Mr. Edward P. Jordan M.B.A.	Chief Commercial Officer	N/D	N/D	1968
Ms. Anette Abrahamsson	Senior Vice President of Regulatory Affairs	N/D	N/D	1969
Christer Hallgren	Senior Vice President of Intellectual Property	N/D	N/D	1962

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in SEK.

Descrizione

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company's product candidates include Dasynoc, a trailblazer, under approval phase for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib, under pivotal studies for the treatment of chronic myeloid leukemia; XS008, based on axitinib, under development for treatment of kidney cancer; and XS00Y under development phase. It has partnership agreements with EVERSANA for the commercialization of Dasynoc, as well as with NerPharMa for commercial production of Dasynoc. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is headquartered in Solna, Sweden.

Governance aziendale

L'ISS Governance QualityScore di Xspray Pharma AB (publ) al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.